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Summary
Breakthrough technologies which now enable the sequen-
cing of individual genomes will irreversibly modify the
way diseases are diagnosed, predicted, prevented and
treated. For these technologies to reach their full potential
requires, upstream, access to high-quality biomedical data
and samples from large number of properly informed and
consenting individuals and, downstream, the possibility to
transform the emerging knowledge into a clinical utility.
The Lausanne Institutional Biobank was designed as an
integrated, highly versatile infrastructure to harness the
power of these emerging technologies and catalyse the dis-
covery and development of innovative therapeutics and
biomarkers, and advance the field of personalised medi-
cine. Described here are its rationale, design and gov-
ernance, as well as parallel initiatives which have been
launched locally to address the societal, ethical and techno-
logical issues associated with this new bio-resource.
Since January 2013, inpatients admitted at Lausanne
CHUV University Hospital have been systematically in-
vited to provide a general consent for the use of their bio-
medical data and samples for research, to complete a stand-
ardised questionnaire, to donate a 10–ml sample of blood
for future DNA extraction and to be re-contacted for future
clinical trials. Over the first 18 months of operation, 14,459
patients were contacted, and 11,051 accepted to participate
in the study.
This initial 18–month experience illustrates that a system-
atic hospital-based biobank is feasible; it shows a strong
engagement in research from the patient population in this
University Hospital setting, and the need for a broad, integ-
rated approach for the future of medicine to reach its full
potential.
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The potential of genomics to
transform medicine
Sequencing the 3–billion base-pairs of an individual gen-
ome for less than 1000 CHF has now become reality. The
first human genome was published in 2003. Four years
later, a seminal study utilising a technology to analyse and
interrogate a couple of million of common single nucle-
otide polymorphisms (SNPs) spread over the entire gen-
ome (i.e. genome-wide association studies, GWAS [1]) was
published. This article was soon followed by hundreds of
such publications (http://www.genome.gov/gwastudies/in-
dex.cfm?pageid=26525384#searchForm) which have re-
vealed a large number of new chromosomal regions as-
sociated with a broad range of medical conditions. Even
more recently, new sequencing technologies have unrav-
elled an abundance of rare, functional variants in the hu-
man genome, secondary to a recent explosive population
growth [2–4]. In a particular series of experiments, sequen-
cing the coding portion of 202 drug target genes in 14,002
individuals (including 3000 individuals from the Lausanne
Figure 1
Chevron diagrams showing the various steps which lead to the
discovery and development of new drugs (upper panel) and
biomarkers (lower panel).
Steps where genomic information and large bio-resources can be
used to help decision making and accelerate the process of
discovery and development are shown in red. Target ID: target
identification; FTIM = first time into man; PoC = proof-of-concept.
Upper part of the chevron diagram adapted from [9].
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area) revealed more than 11,000 amino-acid changing vari-
ants, with the vast majority of them (74%) being novel and
present in only one or two individuals; moreover almost
half of these rare variants were predicted to be functional
with damaging effects on the gene product. In that sense,
these rare variants generate “human knock-out/down” ef-
fects if they lead to loss or reduction of function of their
gene product or if they have a dominant negative effect;
conversely, they may lead to “human over-expressors” of
the gene, in case of gain-of-function mutations or excessive
gene transcription, for instance in the presence of large
number of gene copies [5].
These rare “experiments by nature” represent a blessing for
biomedical research [6]. They open up unprecedented op-
portunities to accelerate the discovery and the development
of innovative therapeutics and biomarkers and, at term, to
tailor medical interventions to the particular needs and the
specific genetic make-up of individuals [7]. This poten-
tial is further accelerated when genetics is combined with
electronic medical records or other sources of phenotyp-
ic data [8]. Bringing new drugs to the market obeys to a
series of well-defined steps [9], and shares many features
in common with the discovery and development of innov-
ative biomarkers [10] (fig. 1). The transition from one step
to the next step depends on usually difficult-to-make go/no-
go decisions, which are based on information which needs
to be gathered using a variety of approaches.
Human genetic information has already proved to be very
instrumental in the discovery of new drug targets.
Examples to illustrate this point are the observations that
humans genetically deficient in CCR5 receptors are resist-
ant to HIV infection, or that individuals lacking PCSK9
have low LDL-cholesterol levels and are protected from
heart disease [11, 12]. These genetic observations on “hu-
man knock-out” have prompted the discovery of CCR5 in-
hibitors and PCSK9 inhibitors [13], respectively. Further
down the pipeline, statins (which up-regulate the LDL-re-
ceptor at the cell surface to accelerate the clearance of LDL
particles) were originally tested and were shown to be ef-
fective (i.e. in proof of concept studies) on a small num-
ber of individuals who were genetically defective in half of
their LDL receptors (i.e. heterozygous familial hypercho-
lesterolemia). The commoditisation of large-scale exome
and, soon, whole genome sequencing to detect carriers of
rare functional mutations opens up the possibility to apply
this paradigm to essentially any new therapeutic in devel-
opment for chronic conditions, with the expectation to lead
to shorter, faster and more decisive proof-of-concept stud-
ies. However, the problem is that given the fact that these
mutations are rare, access to genomic data from large, or
very large number of individuals is required.
As is the case for new drugs, the discovery and develop-
ment of innovative biomarkers becomes a long, expens-
ive, bumpy and risky road going from the discovery of the
biomarker to its validation and the demonstration that the
marker brings clinical benefit (lower panel fig. 1) [10]. Fin-
ally, the prospect of personalising a therapy according to
the genetic (or other biomarker) make-up of an individual
(i.e. “the right drug at the right dose to the right patient”) is
undoubtedly attractive from a conceptual point of view, and
has mostly permeated the oncology field. However, major
efforts are to be made for personalised medicine to reach
maturity and fulfil the expectations of the patients, society
and industry [6].
In any case, there is no doubt that, once commoditised,
high-throughput technologies capable of analysing the en-
tire genome (i.e. genomics), the metabolic profile (meta-
bolomics), and gene expression (transcriptomics) of a par-
ticular liquid or tissue sample, or the environment (expo-
somics), among other *omic approaches integrated into a
“systems medicine” network [14], will irreversibly modify
the way diseases are diagnosed, predicted, prevented and
treated.
The essential role of population
engagement and large bioresources
For the full potential of these *omic technologies to be
realised requires that they are “fed”, upstream, with high-
quality data and samples from large number of properly
informed, engaged, well-phenotyped and consenting indi-
viduals (fig. 2). The roles of these technologies are to
generate new biological data (like whole genome sequen-
cing) and to store, manipulate and analyse these massive
amounts of clinical and biological data (i.e. “Big Data”)
to create new medical knowledge. New knowledge doesn’t
necessarily mean clinical benefit, however. Robust evid-
ence needs to be constructed to demonstrate the clinical
utility of this new knowledge (i.e. clinical benefits for the
patients, and for the society). To get there requires down-
stream of these technologies, the engagement of the pop-
ulation into clinical research and the willingness of the
citizens to participate in clinical trials, which remain the
necessary stepping stone to demonstrate their clinical util-
ity, be it for new interventions or new biomarkers. Finally,
keeping in mind that no new drug or biomarker has reached
the market (and the patients) without the engagement of
Figure 2
Role of bio-resources like BIL in catalysing translational research.
Emerging *omic technologies (genomics, transcriptomics,
metabolomics and others) require access to high-quality data and
samples from large number of individuals engaged in research and
properly consented for the use of their data and specimen. These
technologies generate large amounts of data (i.e. Big Data), which
are converted into new knowledge thanks to information technology
(IT) and bio-informatics. For their clinical utility to be demonstrated,
evidence needs to be built, using clinical research on engaged
citizens and in partnership with other academic groups within the
private sector. The perimeter of the BIL is illustrated using the
green rectangle. CRC = clinical research centre.
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private sectors, innovative public-private partnerships will
need to be created to deliver novel ways to diagnose and
treat diseases, and to monitor the effect of these interven-
tions.
The Lausanne Institutional Biobank (Biobanque Institu-
tionnelle de Lausanne, BIL) was designed to harness the
power of these emerging *omic technologies, and to facilit-
ate selected steps in the discovery and development of new
drugs and biomarkers and in the construction of personal-
ised medicine. More specifically, a major ambition of the
BIL is to “feed”, upstream, these technologies with high-
quality data and samples, and transform, downstream, the
new medical knowledge into benefits for the patients and
the society (fig. 2).
The Lausanne Institutional Biobank
(BIL): design and governance
The construction of large biobanks like the UK Biobank
[15], or smaller bio-resources like CoLaus [16] or the BIL
(http://www.chuv.ch/biobanque) raises a series of issues
which pertain, among others, to the recruitment of the pa-
tients, the access to high-quality medical and phenotypic
data, the legal and ethical framework, the protection of
private data, as well as funding and economical aspects
(fig. 3). The BIL investigators had already participated in
the design, implementation and exploitation of the CoLaus
Study and the Lausanne Oncology Biobank, and had
already experienced that the local population was engaged
and interested in participating in biomedical research.
The BIL project was designed following extensive discus-
sions with health care professionals and experts in biomed-
ical sciences, ethicists and lawyers (more particularly with-
in the frame of the new Law on Research in Humans and
its Ordinances, which were enacted in January 1st, 2014),
and after benchmarking with similar initiatives in the USA,
UK and Asia. It received approval from the Ethics Com-
Figure 3
Landscape of the Lausanne Institutional Biobank (BIL).
Selected challenges associated with the construction of a bio-
resource like the BIL are listed on the left-hand side. Partners in
addressing these challenges are listed on the right-hand side and
the BIL and parallel projects are listed in the middle. GEGH =
Groupe d’Experts sur le Génome Humain (http://www.vd.ch/
actualite/articles/experts-en-medecine-genomique/). SBP = Swiss
Biobanking Platform, at the planning stage. An overview of the local
activities on the societal aspects of genomic medicine, ethics,
privacy protection and personalised medicine is provided in
references [17–19] and [7].
mittee of the Vaud Canton in October 2012. Upon launch-
ing of the BIL project, three parallel initiatives were started
in the Lausanne area, sponsored by the local government
and the UNIL University (i.e. the creation of an Expert
Group in Genome Sciences (GEGH, http://www.vd.ch/ac-
tualite/articles/experts-en-medecine-genomique/)) [17] and
research projects on the ethical aspects of the BIL General
Consent [18], and on privacy protection [19]. In parallel, a
project is under construction for a Swiss National Biobank-
ing Platform (SBP), under the auspices of the Swiss Na-
tional Science Foundation, at the interface with the five
University Hospitals in Switzerland, the ETH domain and
the other Swiss Universities. The initial phase of the BIL
project, which has been identified as a key strategic priority
by the CHUV Hospital (http://www.chuv.ch/
chuv_planstrat201418.pdf), the Lausanne University and
the Vaud Ministry of Health and Social Welfare, has been
funded jointly by these former two institutions for
2014–2015. Upon careful evaluation, it has recently been
decided that the Biobank shall be integrated with the Clin-
ical Research Centre and a dedicated IT group, into the
newly created and funded Platform to Support Clinical Re-
search at CHUV/UNIL.
The design of the BIL is conceptually simple. Each patient
admitted for hospitalisation in the CHUV University Hos-
pital, is informed about the project and is invited to sign the
General Consent for research, to complete a standardised
questionnaire and to donate a 10–ml blood sample for fu-
ture DNA extraction, and consent for future contacts.
The General Consent (http://www.chuv.ch/biobanque/
bil_home/bil-patients-famille/bil-participer/bil-
le_consentement_general.htm) was developed to facilitate
the engagement of participants in clinical research. Indi-
viduals consent for the broad use of their biomedical data
for research, without having to be re-contacted and re-con-
sented for new projects, as long as these projects have been
approved by the local Ethics Committee. In addition, they
consent for their genome to be fully sequenced in the fu-
ture, and accept or not to be re-contacted in case clinically
actionable mutations were to be found once their genome
had been sequenced, and for future clinical research. They
are invited to complete a questionnaire, with standard ques-
tions related to their personal history, their family history,
and phenotypic variables. Given the new Law on Research
on Humans, each patient needs to be informed personally
and to provide written consent (i.e. “opt-in” recruitment).
A team of dedicated nurses, medical assistants and re-
search personnel has been specifically hired and trained
for these tasks. A 10–ml blood sample is collected, usu-
ally on the second day of admission, in fasting condi-
tions, in the wards. The blood is transported to the lab
where it is spun, generally within 1 hour upon collec-
tion. Plasma is isolated and aliquoted into 3 0.5 ml tubes,
which are stored at –80 °C. Similarly, the buffy coat is
isolated and split into two aliquots, stored in two separ-
ate –80 °C freezers for future DNA extraction. A specific
biobanking software has been developed for the annotation
of the patient’s willingness to participate in research and re-
cording and monitoring of samples type and availabilit-
ies.
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The strategic direction of the BIL, and the newly created
Platform it is part of, is supervised by a Steering Group
chaired by the Dean of the Biology and Medical School,
and senior representatives from UNIL and CHUV Direc-
tion and Department Heads. This group oversees the activ-
ity of the BIL operating board. It is also in charge of priorit-
ising which studies will be used as pilots to demonstrate the
use of the platform (see below), and to ensure that funding
is properly used. A separate board, made of patient’s rep-
resentatives, is under construction.
Recruitment was launched on January 7th, 2013. Within
the first eighteen months (i.e. up to June 30th, 2014), a total
of 14,459 patients were contacted and invited to particip-
ate in the project, with 11,051 patients consenting to be
part of the BIL (i.e. a participation rate of 76%). The basic
characteristics of these participants are described in table
1. Experience so far indicates that the approach, which was
designed to have the General Consent presented to all in-
patients by an independent team of recruiters, provides a
significant benefit to the patients, who are better informed
about what clinical research means, it facilitates the work
of the investigators and diminishes the risk of conflict of in-
terest that investigators may have. The ambition of the BIL
is to continue the recruitment at a rate of 10,000 patients
per year.
The Lausanne Institutional Biobank
(BIL): perspectives and opportunities
for research
Along the same strategy which underlined the creation
of the Swiss HIV Cohort Study, CoLaus (ht-
tp://www.colaus.ch/en/cls_home/cls_pro_home/
cls_pro_publications.htm) or other biobanks, the BIL is
constructed to facilitate translational and clinical research
for a variety of investigators locally and regionally. Differ-
Table 1: Characteristics of the first 11,051 participants of the
Lausanne Institutional Biobank.
n 11,051
Males (%) / females (%) 54 /46
Age (mean ± SD) (years) 60 ± 19
Origin (% Swiss) 70
Professional status 40% retired / 26% employee
Religion 37% Catholic / 35% Protestant /
28% other
ent categories of research projects are envisioned with the
BIL, spanning from hospital epidemiology to clinical trials
(table 2). These project pertain to the use of biological
samples for independent validation of biomarkers, for de-
tailed *omic analyses of selected samples and for enrol-
ment of specific patients into future clinical trials. In par-
allel, activities have been envisioned with the other Fa-
culties at the Lausanne University, for a global approach to
new medicine, with partners at the local (EPFL), regional
(University of Geneva) and national level (Swiss Biobank-
ing Platform), for the optimal exploitation of the BIL bio-
resource. In addition, creative partnerships are envisioned
between this publicly funded initiative and private partners,
as a way for “genomic revolution” to benefit the patients
and the population.
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Table 2: Potential for projects to be performed using the BIL bio-resource.
Type of projects Examples
Characteristics of medical care and practice – Hospital epidemiology Impact of drug adverse effects on hospital admissions
Medical care of specific conditions
Discovery of genetic and molecular bases of diseases, biomedical traits or response
to interventions (including pharmacogenetics) – discovery of novel biomarkers using
untargeted *omic technologies
GWAS analysis of clinical conditions and phenotypic traits [20]
In silico GWAS analyses [8]
Genetic analyses of new phenotypes (e.g. facial morphology [21]
Validation of genetic or other biomarkers Confirmation of association between genetic and non-genetic markers on biobanked
samples from well-characterised individuals
Detailed phenotypic analyses on human carriers of null mutations (including
PheWAS) (supporting target validation)
Hormone sensitive lipase [22]
ApoCIII [23]
PCSK9 [11]
Proof-of-concept studies for investigational therapeutics tested on carriers of
selected genetic mutations or carriers of extreme phenotypes
Statins in heterozygous familial hypercholesterolemia [24]
Genetically enriched Phase IIb/III studies on selected participants of biobanks Modelisation in [25]
Predictive and preventive medicine Breast and ovary cancer prevention in carriers of BRCA1/2 mutations [26]
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Figures (large format)
Figure 1
Chevron diagrams showing the various steps which lead to the discovery and development of new drugs (upper panel) and biomarkers (lower
panel).
Steps where genomic information and large bio-resources can be used to help decision making and accelerate the process of discovery and
development are shown in red. Target ID: target identification; FTIM = first time into man; PoC = proof-of-concept. Upper part of the chevron
diagram adapted from [9].
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Figure 2
Role of bio-resources like BIL in catalysing translational research.
Emerging *omic technologies (genomics, transcriptomics, metabolomics and others) require access to high-quality data and samples from large
number of individuals engaged in research and properly consented for the use of their data and specimen. These technologies generate large
amounts of data (i.e. Big Data), which are converted into new knowledge thanks to information technology (IT) and bio-informatics. For their
clinical utility to be demonstrated, evidence needs to be built, using clinical research on engaged citizens and in partnership with other academic
groups within the private sector. The perimeter of the BIL is illustrated using the green rectangle. CRC = clinical research centre.
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Figure 3
Landscape of the Lausanne Institutional Biobank (BIL).
Selected challenges associated with the construction of a bio-resource like the BIL are listed on the left-hand side. Partners in addressing these
challenges are listed on the right-hand side and the BIL and parallel projects are listed in the middle. GEGH = Groupe d’Experts sur le Génome
Humain (http://www.vd.ch/actualite/articles/experts-en-medecine-genomique/). SBP = Swiss Biobanking Platform, at the planning stage. An
overview of the local activities on the societal aspects of genomic medicine, ethics, privacy protection and personalised medicine is provided in
references [17–19] and [7].
Review article: Current opinion Swiss Med Wkly. 2014;144:w14033
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 8 of 8
